Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 11, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 18, 2025
CEOOther
Context
Classification
other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001256153-25-000004
Filed / recorded
Dec 18, 2025, 9:15 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Ovid Therapeutics Inc.
Issuer CIK
1636651
Ticker
OVID
Reporting person
Jeremy M Levin
Relationship
Director, Officer
Officer title
CEO
Security
Series A Warrant (right to buy)
Table
Derivative (Table II)
Transaction date
Dec 11, 2025
Transaction code
P
Shares / units
47,333
Acquired / disposed
Acquired (A)
Shares owned after
47,333
Ownership form
Direct
Amendment
No
Footnotes from the filing
The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.
Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
The Series A Warrants will terminate upon the earlier of (a) the 30th calendar day following date on which we publicly announce the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of our OV4071 product candidate; provided that such 30-calendar day period shall not commence unless and until a registration statement covering the resale of the shares of Common Stock issuable upon exercise of the Series A Warrants is effective; and (b) October 6, 2030.